- Home
- PKBK vs CRBP Comparison
PKBK vs CRBP Comparison
Compare PKBK & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- CRBP
- Stock Information
- Founded
- PKBK 1999
- CRBP 2009
- Country
- PKBK United States
- CRBP United States
- Employees
- PKBK N/A
- CRBP N/A
- Industry
- PKBK Major Banks
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- CRBP Health Care
- Exchange
- PKBK Nasdaq
- CRBP Nasdaq
- Market Cap
- PKBK 249.7M
- CRBP 227.3M
- IPO Year
- PKBK N/A
- CRBP N/A
- Fundamental
- Price
- PKBK $23.01
- CRBP $18.55
- Analyst Decision
- PKBK
- CRBP Strong Buy
- Analyst Count
- PKBK 0
- CRBP 7
- Target Price
- PKBK N/A
- CRBP $65.86
- AVG Volume (30 Days)
- PKBK 18.6K
- CRBP 376.5K
- Earning Date
- PKBK 10-18-2024
- CRBP 11-19-2024
- Dividend Yield
- PKBK 3.15%
- CRBP N/A
- EPS Growth
- PKBK N/A
- CRBP N/A
- EPS
- PKBK 2.34
- CRBP N/A
- Revenue
- PKBK $63,151,000.00
- CRBP N/A
- Revenue This Year
- PKBK N/A
- CRBP N/A
- Revenue Next Year
- PKBK N/A
- CRBP N/A
- P/E Ratio
- PKBK $9.96
- CRBP N/A
- Revenue Growth
- PKBK N/A
- CRBP N/A
- 52 Week Low
- PKBK $15.24
- CRBP $3.03
- 52 Week High
- PKBK $23.44
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- PKBK 66.50
- CRBP 40.98
- Support Level
- PKBK $20.88
- CRBP $18.18
- Resistance Level
- PKBK $23.44
- CRBP $20.77
- Average True Range (ATR)
- PKBK 0.43
- CRBP 1.06
- MACD
- PKBK 0.17
- CRBP 1.12
- Stochastic Oscillator
- PKBK 74.10
- CRBP 56.20
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.